Videos
Downloads
Press Release – 6 Nov 18 – Abzena announces 20m$ investment
Download the 6th November 2018 release.
DownloadMHC Associated Peptide Proteomics
Case Study MAPPs for Vaccine Design To identify MHC class I presented antigens derived from influenza strain H1N1, two[...]
DownloadWorld ADC Presentation 2017
Abzena’s presentation at World ADC 2017 given by Campbell Bunce – Senior Vice President Technical Operations.
DownloadComposite Proteins™ Fact Sheet
More information on Abzena’s Composite Protein™ technology. Protein Deimmunisation Technical Flyer
DownloadOptimisation of Pharmacokinetics Fact Sheet
Information on a our PEGylation technologies, including a TheraPEG case study on the PEGylation of interferon (IFN) a-2b
DownloadComposite Human Antibodies™ Fact Sheet
More information on our antibody humanisation and deimmunisation technology, including a case study on the deimmunisation[...]
DownloadiTope™ and TCED™ Fact Sheet
More information on Abzena’s iTope™ and TCED™ technology including a detailed look at the results.
DownloadEpiScreen™ Time Course T Cell Assay Fact Sheet
More information on the EpiScreen™ time course T cell assay and a case study showing the potential immunogenicity[...]
DownloadEvents
WADC London 2022
29 March 2022
Our team, Nicolas Camper, Jonathan Cruickshank, Swati Chatterjee, Patrick Haddad and Mark Frigerio are excited to[...] Read more
WEBINAR – ADC Developability for successful lead candidate selection
22 September 2021
We are doing a webinar on the 22nd September at 3pm BST/10am EDT. Register for the webinar here. Antibody-drug conjugates[...] Read more
References
Stability of Maleimide-PEG and Mono-Sulfone-PEG Conjugation to a Novel Engineered Cysteine in the Human Hemoglobin Alpha Subunit
In order to use a Hemoglobin Based Oxygen Carrier as an oxygen therapeutic or blood substitute, it is necessary to[...] Read more
Addressing the Challenges of Bioconjugate Medicines
The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-,[...] Read more
Antibody-Drug Conjugates
This volume looks at key methodologies that are commonly used across antibody drug conjugates (ADCs) programs. The[...] Read more
Integrating ADC Manufacturing for the Future
Antibody–drug conjugates (ADCs) in development target many indications beyond cancer and consist of a multitude of[...] Read more
Antibody Drug Conjugates of Cleavable Amino-alkyl and Aryl Maytansinoids
Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have[...] Read more
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized[...] Read more
Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody–Drug Conjugate Payload
Antibody–drug conjugates (ADCs) represent an important class of emerging cancer therapeutics. Recent ADC development[...] Read more
Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload
Antibody–drug conjugates (ADCs) represent an important class of emerging cancer therapeutics. Recent ADC development[...] Read more
Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates
Antibody-drug conjugates (ADCs) are a promising class of anticancer agents which have undergone substantial development[...] Read more
Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents
Antibody drug conjugates (ADCs) have begun to have a tremendous impact on the treatment of cancer and other pathological[...] Read more
News
Abzena announces appointment of Petra Dieterich as Scientific Lead
Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of[...] Read more
Abzena Opens a New Biologics Testing Lab to Support Partners Programs
Abzena, a leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of[...] Read more
Abzena Secures $65 Million in Additional Funding to Accelerate Growth and Expand Capacity
Investment from Welsh, Carson, Anderson & Stowe and Biospring Partners allows Abzena to expand manufacturing[...] Read more
Abzena, Alira Health and Oncodesign launch DRIVETM-Biologics to support access to specialist services from discovery to clinical development for oncology and inflammation
Consortium provides a unique integrated solution with specialist services, from biologics discovery to clinical and[...] Read more
Abzena appoints Kevin Lundquist as Chief Financial Officer
Cambridge, UK and San Diego, CA, February 1, 2022 – Abzena, a leading Partner Research Organization (PRO) for[...] Read more
Abzena appoints Jim Kennamer as SVP and Site Head of North Carolina
Cambridge, UK and San Diego, CA, January 20, 2022 – Abzena, a leading Partner Research Organization (PRO) for[...] Read more
Abzena Promotes Troy Wright to Senior Vice President and Global Head of Quality
Cambridge, UK and San Diego, CA, 15 December 2021 – Abzena, the leading Partner Research Organization (PRO) for[...] Read more
Abzena Promotes Dr. Louise Duffy as Chief Technical Officer
Cambridge, UK and San Diego, CA, 26 October 2021 – Abzena, the leading Partner Research Organization (PRO) for[...] Read more
Abzena and evitria announce partnership to provide best in class lead candidate selection.
Abzena, a Partner Research Organization for integrated discovery to GMP solutions for biologics and[...] Read more
Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers.
Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and[...] Read more
Abzena announces location of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors
Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of[...] Read more